What Sparked Quince Therapeutics (QNCX) Stock To Rise 53% After Hours
Quince Therapeutics Inc. (NASDAQ:QNCX) shares increased 52.99% in the after-hours session to $0.34 on Thursday.
According to Benzinga Pro data, the stock of the California-based biotech closed regular trading down 63.03% at $0.23.
Company Engages Financial Advisor for Strategic Alternatives
Quince Therapeutics filed a Securities and Exchange Commission filing on Thursday, disclosing that it engaged New York-based LifeSci Capital on Monday as its exclusive financial advisor to assist with restructuring activities and evaluate strategic alternatives, including a reverse merger.
The company also reported that the NEAT clinical trial, a Phase 3, randomized, double-blind, placebo-controlled study for its lead drug candidate eDSP, did not meet its primary or secondary endpoints.
Financial Position and Nasdaq Listing Risk
As of Dec. 31, 2025, Quince Therapeutics had about $5.8 million in cash, $11.9 million in short-term investments and $16.4 million outstanding on its unsecured European Investment Bank line of credit, according to preliminary unaudited estimates.
The filing states that since Jan. 29, the closing price of the company’s common stock on the Nasdaq Global Select Market has been less than $1.00 clouding delisting fears.
Trading Metrics, Technical Analysis
Quince Therapeutics has a Relative Strength Index (RSI) of 28.57.
The market capitalization of the late-stage biotechnology company stands at $12.56 million, with its shares reaching a 52-week high of $4.55 and a low of $0.13.
Over the past 12 months, the stock has fallen 84.12%.
Currently, the stock is positioned at approximately 2.3% of its 52-week range, near the low end.
QNCX’s steep drop and weak position indicate that any potential recovery would require clear confirmation before investors consider taking significant action.
Benzinga's Edge Stock Rankings indicate that QNCX has a negative price trend across all time frames.
Photo Courtesy: Champ008 on Shutterstock.com
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Gold recovers from YTD low, retakes $3,900; Fed hike bets and bullish USD to cap gains
Cerebras (CBRS.US) Cloud Business Soars, Masking Hardware Decline; OpenAI Supports Half of Cloud Revenue
Cerebras achieved record Q3 revenue, but hardware income dropped by nearly 30%, while cloud business accounted for two-thirds of total revenue. OpenAI contributed $72.4 million. The company raised its full-year guidance and expects Q4 to be close to breakeven.
Microsoft (MSFT.US) offers voluntary buyout packages to about 60,000 employees: Structural divergence in U.S. employment under AI transformation
In 2026, the U.S. labor market is characterized by both low layoffs and weak hiring. Companies like Microsoft and American Express are leveraging AI to optimize their workforce, while data centers are driving growth in the construction sector. However, entry-level white-collar jobs face increasing pressure, with real wages experiencing negative growth and structural transformation risks becoming more prominent.
Crypto prices
More
